Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study—authors’ response
Authors:
Open Access
- 19 August 2019
- journal article
- letter
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 74 (11) , 3403-3404
Abstract
No abstract availableFunding Information
- AbbVie
- Bristol-Myers Squibb
- Gilead
- Janssen
- MSD
This publication has 5 references indexed in Scilit:
- Comment on: Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective studyJournal of Antimicrobial Chemotherapy, 2019
- Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in FranceJournal of Antimicrobial Chemotherapy, 2019
- Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective studyJournal of Antimicrobial Chemotherapy, 2019
- PEPDar: A randomized prospective noninferiority study of ritonavir‐boosted darunavir for HIV post‐exposure prophylaxisHIV Medicine, 2016
- National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011Journal of Antimicrobial Chemotherapy, 2013